Multiple proposed biological pathways

The term 'Multiple proposed biological pathways' is a descriptive classification rather than a specific molecular target, such as a protein, receptor, or enzyme. It is commonly used in scientific literature and clinical trial registries to describe the complex, pleiotropic effects of drugs or interventions whose precise mechanism of action involves the simultaneous modulation of several distinct signaling cascades (PubMed). For example, compounds like metformin or certain dietary supplements are often described this way because they influence various metabolic and inflammatory pathways rather than binding to a single 'silver bullet' target. Because this designation lacks a unique identifier in biological databases like UniProt or the IUPHAR/BPS Guide to Pharmacology, it is considered an incorrect or non-specific entry for structured target identification. For therapeutic development, it is essential to deconstruct this term into specific, measurable molecular targets to facilitate rational drug design and regulatory approval. This phrase often serves as a placeholder when the full interactome of a drug is still being elucidated through systems biology approaches. Consequently, it does not represent a druggable entity in the traditional sense but rather a summary of observed polypharmacology.

Not applicable